Vaxcyte, Inc.
PCVX
$34.60
$1.705.17%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -32.93% | 19.87% | -35.45% | 47.44% | -95.11% |
| Total Depreciation and Amortization | 6.55% | 29.13% | 12.52% | 4.85% | 18.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 168.45% | -25.08% | 75.11% | -39.54% | 912.06% |
| Change in Net Operating Assets | -108.51% | 474.90% | 89.45% | -293.97% | 11.99% |
| Cash from Operations | -83.50% | 49.99% | 23.71% | -23.53% | -123.83% |
| Capital Expenditure | 21.15% | 2.31% | -222.90% | 78.85% | -677.61% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 40.03% | -2,021.71% | 90.56% | -1,117.55% | 45.66% |
| Cash from Investing | 39.24% | -1,040.49% | 82.17% | -3,139.07% | -162.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.61% | 1,274.14% | -86.50% | 26,702.68% | -94.01% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 88.38% | -1,552.39% | 82.91% | -901.82% | 87.33% |
| Cash from Financing | -99.68% | 1,272.71% | -86.51% | 29,815.76% | -94.37% |
| Foreign Exchange rate Adjustments | 124.21% | -295.46% | -123.26% | 178.91% | -830.92% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -224.56% | 672.73% | -143.37% | 244.95% | -1,130.37% |